With Carboxylic Acid, Ester Or Metal Salt Thereof Patents (Class 514/163)
  • Publication number: 20120003314
    Abstract: A timed or delayed release oral composition delivery system for the treatment of colonic disorders and diseases is provided. According to one aspect, a delayed release oral pharmaceutical composition includes an active core comprising a therapeutically effective amount of 5-amino salicylic acid (i.e., mesalamine); a primary coating composition disposed around the active core, wherein the primary coating composition includes an enteric polymer; and a secondary coating composition disposed around the primary coating composition, wherein the secondary coating composition includes a ratio mixture of ethyl cellulose and hydroxypropyl methylcellulose.
    Type: Application
    Filed: September 15, 2011
    Publication date: January 5, 2012
    Applicant: ROXANE LABORATORIES, INC.
    Inventors: Vinay H. SHUKLA, Eric M. SPILLER
  • Publication number: 20110301130
    Abstract: The invention relates to a topical gel composition for use in the treatment of actinic keratosis comprising (a) an active agent for treatment of actinic keratosis, (b) a keratolytically active agent, (c) a gel former, and (d) an organic solvent.
    Type: Application
    Filed: June 29, 2009
    Publication date: December 8, 2011
    Applicant: ALMIRALL HERMAL GMBH
    Inventors: Manfred Melzer, Carmen Matthies, Klaus Treudler, Christoph Willers, Henning Mallwitz
  • Publication number: 20110237555
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.
    Type: Application
    Filed: June 6, 2011
    Publication date: September 29, 2011
    Applicant: Action Medicines
    Inventors: Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Morgan, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Publication number: 20110230816
    Abstract: The present disclosure provides hydrogels that are suitable for drug delivery. In embodiments, hydrogels of the present disclosure may be used for transdermal delivery of bioactive agents, including drugs. The hydrogels of the present disclosure may also be useful as conductive compositions for use with electrodes.
    Type: Application
    Filed: August 31, 2010
    Publication date: September 22, 2011
    Applicant: TYCO HEALTHCARE GROUP LP
    Inventor: Warren Copp-Howland
  • Patent number: 8017138
    Abstract: A method for the topical treatment of skin aging and acne and the improvement of skin appearance is disclosed. Compositions for use in this method and a kit containing such compositions are also disclosed. In some of the embodiments of the invention, either one, or both, of the acid composition and neutralizing composition useful in the method for the topical treatment of skin aging and acne and the improvement of skin appearance are of low viscosity. The compositions and methods are effective but gentle enough to be suitable for daily home use by the consumer.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: September 13, 2011
    Inventor: Dennis Gross
  • Publication number: 20110217252
    Abstract: It is described the use of propionyl L-carnitine for treating disturbances of the skin such as cellulite.
    Type: Application
    Filed: November 5, 2009
    Publication date: September 8, 2011
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventor: Aleardo Koverech
  • Publication number: 20110178047
    Abstract: Disclosed are novel oxylipins, referred to herein as docosanoids, that are derived from C22 polyunsaturated fatty acids, and method of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic acid (DTAn-6: C22:4n-6) as substrates for the production of novel oxylipins, and to the oxylipins produced thereby. Also disclosed is the use of DPAn-6, DPAn-3, DTAn-6, and/or the oxylipins derived therefrom, and/or novel docosanoids derived from the structures of C22 fatty acids, in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. The invention also relates to novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of LCPUFA-derived oxylipins, and particularly, docosanoids.
    Type: Application
    Filed: December 29, 2010
    Publication date: July 21, 2011
    Applicant: MARTEK BIOSCIENCES CORPORATION
    Inventors: Linda Arterburn, William Barclay, Bindi Dangi, James Flatt, Jung Lee, Mary Van Elswyk
  • Publication number: 20110159048
    Abstract: The present invention relates to methods and compositions for reducing Distress Dysfunction by restoring and maintaining homeostatic balance in the neurotransmitter systems underlying the Stress Response and the experience of distress and hedonic tone. Distress Dysfunction refers to the experience of dysfunctional emotional and physical distress that interferes with the individual's quality of life and functioning.
    Type: Application
    Filed: December 20, 2010
    Publication date: June 30, 2011
    Inventors: Steven Crain, William E. Crain, Stanley M. Crain, Michael Crain
  • Publication number: 20110152223
    Abstract: Disclosed is an agent for preventing/treating ANCA-related vasculitis and/or preventing the recurrence of ANCA-related vasculitis. Also disclosed is a therapeutic method using the agent. Specifically disclosed is a pharmaceutical composition comprising at least one member selected from the group consisting of eicosapentaenoic acid, a pharmaceutically acceptable salt thereof and an ester thereof as an active ingredient. The pharmaceutical composition is useful for the prevention of recurrence of ANCA-related vasculitis, the treatment of chronic ANCA-related vasculitis, and the prevention and treatment of rapidly progressive glomerulonephritis (RPGN).
    Type: Application
    Filed: August 21, 2009
    Publication date: June 23, 2011
    Inventors: Junichi Hirahashi, Makoto Arita, Keiichi Hishikawa, Toshiro Fujita, Masanori Nakakuki
  • Publication number: 20110152222
    Abstract: The present invention relates to the use of a compound of Formula (I??) or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and/or prophylaxis of arthritis and pain.
    Type: Application
    Filed: August 15, 2007
    Publication date: June 23, 2011
    Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego
  • Publication number: 20110151024
    Abstract: The present invention relates to compositions and methods for preventing migraines. The migraine prophylaxis composition is a single dosage form comprising at least one form of elemental magnesium and at least one NSAID. The prophylaxis composition, comprising at least one form of elemental magnesium and a therapeutically effective concentration of acetylsalicylic acid may also provide cardiac protection and prevent cardiovascular diseases.
    Type: Application
    Filed: March 1, 2011
    Publication date: June 23, 2011
    Inventor: Alexander Mauskop
  • Publication number: 20110144055
    Abstract: The use of a pharmaceutical regimen to deter in an individual, as the individual ages, the development of a cardiovascular disease (CVD) or Alzheimer's disease or to treat an individual who has CVD or Alzheimer's, the individual ingesting on a daily basis a regimen comprising pharmaceutically effective amounts of magnesium salicylate and naproxen, the amount of the magnesium salicylate being no greater than about 260 mg, and also the use of a pharmaceutical regimen to treat an individual who has Type 2 diabetes, the regimen being ingested daily by the individual and comprising pharmaceutically effective amounts of at least one glucose-lowering drug and magnesium salicylate in an amount no greater than about 260 mg.
    Type: Application
    Filed: September 4, 2009
    Publication date: June 16, 2011
    Inventors: Anthony I. Rozmanith, Jolan S. Rozmanith
  • Patent number: 7935689
    Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed, compound of the formula (I): wherein n is 1 or 2; m is 0, 1, 2, 3, 4, 5, 6, 7 or 8; q is 0 or 1; t is 0 or 1; R1 is alkyl having from 1 to 3 carbon atoms; R2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; R3 and R4 together are alkyl having two or three carbon atoms; or R3 and R4 are the same as each other and each is methyl or ethyl; R5 is hydrogen or alkyl having from one to six carbon atoms.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: May 3, 2011
    Assignee: Wellstat Therapeutics Corporation
    Inventors: Shalini Sharma, Reid W. von Borstel
  • Patent number: 7928092
    Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: April 19, 2011
    Assignee: AGI Therapeutics Ltd.
    Inventors: John Devane, Jackie Butler
  • Publication number: 20110082119
    Abstract: A highly safe and effective prophylactic/ameliorating or therapeutic agent for NACH and the method for using the same are provided. A prophylactic/ameliorating or therapeutic agent for NASH containing a combination of at least one first ingredient selected from the group consisting of an ?3PUFA and pharmaceutically acceptable salts and esters thereof and at least one second ingredient selected from the group consisting of (a) a biguanide hypoglycemic agent, (b) a nonsteroidal anti-inflammatory drug, (c) a 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitor, and (d) an angiotensin II receptor blocker as the active ingredients; and its method of use.
    Type: Application
    Filed: June 12, 2009
    Publication date: April 7, 2011
    Inventor: Takashi YANO
  • Publication number: 20110064813
    Abstract: The invention relates to a compound and administration of the compound to mammals containing salsalate in a nanofied form to reduce inflammation. This compound and administration may be combined with caffeine, omega 3 fatty acids, sodium bicarbonate, and/or simvastatin to further benefit that administration.
    Type: Application
    Filed: August 6, 2010
    Publication date: March 17, 2011
    Inventor: Charles Vaughn
  • Publication number: 20110064683
    Abstract: Described are personal care compositions, comprising an aqueous dispersion comprising an ethylene acrylic acid copolymer and a least one cosmetically acceptable surfactant, emollient, or cosmetic active.
    Type: Application
    Filed: September 15, 2010
    Publication date: March 17, 2011
    Applicants: Technology Corporation)
    Inventors: Susan L. Jordan, Tatiana V. Drovetskaya
  • Publication number: 20110052694
    Abstract: Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.
    Type: Application
    Filed: August 31, 2010
    Publication date: March 3, 2011
    Applicant: ALLTRANZ INC.
    Inventors: Audra Lynn Stinchcomb, Stan Lee Banks, Miroslaw Jerzy Golinski, Jeffery Lynn Howard, Dana Carmel Hammell
  • Publication number: 20110034425
    Abstract: This invention relates to a method of treating acute myelogenous leukemia with TPA along with Dexamethasone and choline magnesium trisalicylate.
    Type: Application
    Filed: August 4, 2010
    Publication date: February 10, 2011
    Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
    Inventor: Roger Strair
  • Patent number: 7879827
    Abstract: The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon cancer. More particularly, these derivatives comprise a hydrogen sulfide releasing moiety linked via an azo, an ester, an anhydride, a thioester or an amide linkage to a molecule of 4- or 5-aminosalicylic acid. Furthermore, the present invention provides a process for preparing these compounds and their use for treating IBD and IBS and the prevention/treatment of colon cancer.
    Type: Grant
    Filed: February 10, 2009
    Date of Patent: February 1, 2011
    Assignee: Antibe Therapeutics Inc.
    Inventors: John L. Wallace, Giuseppe Cirino, Giuseppe Caliendo, Anna Sparatore, Vincenzo Santagada, Stefano Fiorucci
  • Publication number: 20110021468
    Abstract: This invention relates to methods for the treatment of atherosclerotic cardiovascular disease using a non-acetylated forms of salicylate, e.g., salsalate and/or trilisate.
    Type: Application
    Filed: July 3, 2008
    Publication date: January 27, 2011
    Applicant: JOSLIN DIABETES CENTER, INC.
    Inventors: Steven Shoelson, Allison B. Goldfine
  • Publication number: 20100310650
    Abstract: A pharmaceutical composition for the oral administration of omega polyenoic fatty acids combined with one or more active principles incompatible therewith, is described; also described is a process for preparing said pharmaceutical composition.
    Type: Application
    Filed: June 26, 2007
    Publication date: December 9, 2010
    Inventor: Roberto Valducci
  • Publication number: 20100311700
    Abstract: A transdermal preparation for external use which contains a photosensitive NSAID and a UV blocker having a high ability to migrate into the skin. Thus, it becomes possible to ensure, in a transdermal preparation for external use containing a NSAID, the inhibition of the onset of light-induced non-immunological or immunological skin symptoms by the above-described component.
    Type: Application
    Filed: April 29, 2010
    Publication date: December 9, 2010
    Applicant: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Kazuhisa Yoshitake, Kenji Atarashi, Tetsuji Kuwahara, Koichi Ikesue, Michinori Sakai, Yoshiaki Hashimoto, Kiyomi Tsuruda
  • Patent number: 7825106
    Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid, and pharmaceutically acceptable salts and pro-drugs thereof, to affected areas of the intestine, i.e., distal gut. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: November 2, 2010
    Assignee: AGI Therapeutics Ltd.
    Inventors: John Devane, Jackie Butler
  • Publication number: 20100239552
    Abstract: This invention is directed to pharmaceutical combinations comprising an antioxidant agent, an anti-inflammatory agent, and optionally at least one other anti-diabetic agent useful for treating metabolic disorders. This invention also encompasses pharmaceutically acceptable compositions comprising an antioxidant agent, an anti-inflammatory agent, optionally at least one other anti-diabetic agent, and at least one pharmaceutically acceptable carrier.
    Type: Application
    Filed: March 16, 2010
    Publication date: September 23, 2010
    Applicant: GENMEDICA THERAPEUTICS SL
    Inventors: Eric Mayoux, Luc Marti Clauzel, Silvia Garcia-Vicente, Marta Serrano Munoz, Antonio Zorzano Olarte, Alec Mian
  • Publication number: 20100204188
    Abstract: The present invention provides combinations, for treatment of subjects suffering from or at high risk of developing diseases and disorders involving expression of peroxisome proliferator-activated receptors (PPAR). The combinations include abscisic acid and one other bioactive agent, which together provide synergistic effects toward treatment or blocking of development of the disease or disorder. In exemplary embodiments, a combination of abscisic acid and a thiazolidinedione (TZD) is provided for increased insulin sensitivity and improved (i.e., reduced) obesity-induced inflammation.
    Type: Application
    Filed: January 28, 2010
    Publication date: August 12, 2010
    Applicant: Virginia Tech Intellectual Properties, Inc.
    Inventors: Josep BASSAGANYA-RIERA, Amir Guri, Raquel Hontecillas
  • Publication number: 20100196343
    Abstract: Accordingly, a need has arisen for improved compositions, methods, devices, and systems for skin care including, without limitation, topical compositions and phototherapy devices and methods. A skin care method may comprise, in some embodiments, contacting at least a portion of the skin of a subject with a homogeneous, stable, self-foaming composition, illuminating the at least a portion of the skin exclusively with light of a desired wavelength (e.g., from about 390 nm to about 430 nm, and contacting the at least a portion of the skin with an anti-oxidant serum composition.
    Type: Application
    Filed: September 4, 2009
    Publication date: August 5, 2010
    Inventors: Michael P. O'Neil, Joel Rubin, Drake Stimson
  • Publication number: 20100189669
    Abstract: Personal care compositions containing an active selected from the group consisting of phlorogine, phlorgine BG, deoxyArbutin, sucrose dilaurate, bakuchiol, pyrenoine, millet, arlatone dioic acid, cinnamic acid, ferulic acid, achromaxyl, methyl nicotinamide, oil soluble licorice extract, folic acid, undecylenic acid, zinc undecylenate, L-tryptophan, thiamine HCl, hexylresorcinol, lipidami red vine, dragosine, methyl gentisate, inositol, symdiol 68, laminaine, their salts, their derivatives, their precursors, and/or combinations thereof. Methods for regulating the condition of mammalian keratinous tissue by topically applying the personal care compositions are also provided.
    Type: Application
    Filed: January 25, 2010
    Publication date: July 29, 2010
    Inventor: Tomohiro Hakozaki
  • Publication number: 20100189761
    Abstract: Methods for prevention or treatment of capsular contracture following surgical implants and other fibrosis related conditions comprising applying a topical composition comprising a pharmaceutically acceptable keratolytic, a pharmaceutically acceptable protein denaturant, a hydrating agent, and combinations thereof are disclosed.
    Type: Application
    Filed: November 12, 2009
    Publication date: July 29, 2010
    Applicant: J&E Solutions, LLC
    Inventors: Jeanne V. FRIEDMAN, Elsa M. Raskin
  • Publication number: 20100184727
    Abstract: A muscarinic receptor antagonist is useful for the treatment or prevention of a condition associated with excess sebum production or excretion.
    Type: Application
    Filed: June 7, 2007
    Publication date: July 22, 2010
    Applicant: SUMMIT (CAMBRIDGE) LIMITED
    Inventors: Alan Geoffrey Roach, Paul Goldsmith
  • Publication number: 20100184728
    Abstract: The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema. In one embodiment, a composition suitable for administration as an enema comprises an effective amount of 5-ASA and a steroid such as budesonide or hydrocortisone. The subject invention also concerns compositions formulated for oral administration. In one embodiment, a composition comprises alpha-lipoic acid, and/or N-acetyl-L-cysteine (N-A-C), and/or L-glutamine. The alpha-lipoic acid can be racemic alpha-lipoic acid, R-lipoic acid, or R-dihydro-lipoic acid. Methods of the invention include administration of compounds or compositions of the invention.
    Type: Application
    Filed: June 13, 2008
    Publication date: July 22, 2010
    Applicant: THERAPEUTIC RESEARCH LLC
    Inventor: Jay Pravda
  • Publication number: 20100159035
    Abstract: The invention provides a therapeutic composition, simultaneously containing (1) at least one polar solvent, selected from the group of a short-chain mono-alcohol and a diol; (2) between about 2% and about 25% of at least two keratolytic agents; and (3) a therapeutically safe and effective concentration of a antifungal agent It further provides a kit, consisting of an occlusive device and a therapeutic composition, useful for treatment of fungal skin infection.
    Type: Application
    Filed: April 10, 2007
    Publication date: June 24, 2010
    Inventor: Avner Shemer
  • Publication number: 20100159031
    Abstract: Compositions and methods for treating or preventing fungal infections of the nail are provided. The topical composition includes the use of chlorine dioxide, chlorite salts, benzoyl peroxide, an alpha hydroxy acid, antifungal and antibiotic agents. Also provided is a heat-generating device for use in treating at least one nail infected with fungus and a toe sock device.
    Type: Application
    Filed: October 7, 2009
    Publication date: June 24, 2010
    Inventor: Karen C. Swenholt
  • Publication number: 20100158993
    Abstract: Topical alcoholic gel compositions are disclosed that are useful for delivering therapeutic levels of an NSAID to target in and below the skin. The compositions comprise a topically active drug, an alcoholic solvent, a polymeric thickener, and optionally a keratolytic agent. In one embodiment, excellent viscosity for dermal application is attained without the need of a step for neutralizing the pH of the composition. Alcoholic and alcohol-free topical compositions comprising an NSAID prodrug are also disclosed. The compositions are particularly useful for the treatment of pseudofolliculitis barbae.
    Type: Application
    Filed: December 21, 2009
    Publication date: June 24, 2010
    Applicant: ISW Group, Inc.
    Inventors: Monique Spann-Wade, Anthony Ward
  • Publication number: 20100092400
    Abstract: Provided, among other things, is a delivery module for water-based salicylic acid composition comprising: an aerosol delivery system; within the aerosol delivery system, the salicylic acid composition comprising 0.5% or more salicylic acid by weight, lipophilic component(s), and a frothing agent, the salicylic acid composition having a viscosity low enough to support aerosol delivery, and the salicylic acid composition effective to form a foam upon propellant-driven aerosol delivery; and within the aerosol delivery system, a propellant, wherein the salicylic acid composition is non-irritating and has a non-watery feel.
    Type: Application
    Filed: October 15, 2009
    Publication date: April 15, 2010
    Applicant: QUINNOVA PHARMACEUTICALS, INC.
    Inventors: Mats Silvander, Jeffrey S. Day, Linda M. Mahoney, Christopher Nelson Hensby
  • Patent number: 7691832
    Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention contains N-acetylcysteine disposed in a pharmaceutically acceptable carrier for oral or rectal delivery for treating such inflammatory bowel diseases by topical application within the colon.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: April 6, 2010
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: Richard F. Harty
  • Publication number: 20100063009
    Abstract: A combination comprising (a) at least one 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol component, and (b) at least one non-steroidal anti-inflammatory drug (NSAID) component; a pharmaceutical composition and a dosage form comprising such as combination, and a method of treating pain and/or ostheoarthritis in a mammal characterized in that components (a) and (b) are administered simultaneously or sequentially to said mammal, in which component (a) may be administered before or after component (b), and in which components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.
    Type: Application
    Filed: September 4, 2009
    Publication date: March 11, 2010
    Applicant: GRUENENTHAL GmbH
    Inventors: Petra Bloms-Funke, Klaus Schiene
  • Patent number: 7638507
    Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: December 29, 2009
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: Richard F. Harty
  • Publication number: 20090318394
    Abstract: Disclosed are compositions containing DHA and DPAn-6 and methods of administering and using the same to treat or prevent at least one symptom of inflammation or neurodegeneration or disease states associated with inflammation or neurodegeneration. Also discloses are compositions containing specific dosages and/or ratios of long chain polyunsaturated fatty acids that are particularly effective in reducing or preventing symptoms of inflammation or neurodegeneration.
    Type: Application
    Filed: January 21, 2009
    Publication date: December 24, 2009
    Inventors: Julie Nauroth, Linda Mary Arterburn, Mary Van Elswyk
  • Publication number: 20090312292
    Abstract: The invention relates to anti-microbial compositions useful against a wide range of microorganisms undesirable on a wide variety of materials, including food, food contact and non-food contact surfaces, and surfaces in industrial, recreational, health care, and other institutional environments. More particularly, the anti-microbial compositions comprise peracetic acid in combination with a) citric acid or a salt and b) salicylic acid or a salt in aqueous solution.
    Type: Application
    Filed: December 20, 2007
    Publication date: December 17, 2009
    Applicant: FMC CORPORATION
    Inventors: John M. Rovison, Donald Lapham, III, Shibu Abraham, Mary Homan
  • Publication number: 20090238763
    Abstract: The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for non-steroidal anti-inflammatory agents (NSAIAs), which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes.
    Type: Application
    Filed: January 9, 2009
    Publication date: September 24, 2009
    Inventors: Chongxi Yu, Lina Xu
  • Publication number: 20090203655
    Abstract: This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical inflammation in diabetic and prediabetic patients. Methods of the invention comprise administration of DHA alone and in combination with antiplatelet drugs.
    Type: Application
    Filed: February 3, 2009
    Publication date: August 13, 2009
    Applicant: Martek Biosciences Corporation
    Inventors: Linda Arterburn, James Hoffman, Harry Oken, Mary Van Elswyk
  • Publication number: 20090202457
    Abstract: The present invention relates to an exfoliating composition. The composition comprises a mixture. The mixture comprises phenolsulfonic acid, guaiacolsulfonic acid, and optionally sulfosalicylic acid and citric acid.
    Type: Application
    Filed: March 9, 2009
    Publication date: August 13, 2009
    Inventor: Michael Basara
  • Publication number: 20090192126
    Abstract: A composition which is adapted for oral consumption and which is in the form of a substantially homogeneous aqueous emulsion, suspension or dispersion comprising salicylic acid, or a C1 to C6 alkyl ester thereof, and docosahexaenoic acid (DHA) can exhibit an anti-inflammatory effect in skin.
    Type: Application
    Filed: April 5, 2007
    Publication date: July 30, 2009
    Inventors: John Casey, Alexander Gordon James, Gail Jenkins, Linda Jane Wainwright
  • Patent number: 7544349
    Abstract: There are described personal care compositions containing a) one or more dibenzoylmethane sunscreening agents; and b) a photostablising amount of a salicylate ester of formula (1): (2-OH)Ph-(CO)—O—R, wherein R represents an alkyl group consisting of a chain of from 7 to 16 carbon atoms substituted by at least one group selected from methyl and ethyl. The compound of formula (1) is preferably isodecyl salicylate or isotridecyl salicylate. The salicylate esters of formula (1) have a stabilizing effect on the compositions. The salicylate esters prevent or inhibit degradation of the sunscreening agents which would otherwise lead to a reduction in the efficacy of the sunscreening agents and an increase in the deleterious effects of exposure to sunlight on the user of the compositions or on the compositions themselves.
    Type: Grant
    Filed: July 31, 2002
    Date of Patent: June 9, 2009
    Assignee: The Boots Company, PLC
    Inventors: Jane Evison, Janet Palin, Edward Galley
  • Publication number: 20090124574
    Abstract: The presently described embodiments are directed to compositions that include one or more carotenoid analogs or derivatives for use in the treatment of a disorder associated with platelet aggregation. Certain embodiments provide for the use of said carotenoid analogs or derivatives in preparing compositions suitable for use in such treatments. Further embodiments provide for pharmaceutical compositions that include one or more carotenoid analogs or derivatives in combination with one or more additional compositions or medicaments suitable for the treatment of a disorder associated with platelet aggregation.
    Type: Application
    Filed: March 24, 2008
    Publication date: May 14, 2009
    Inventors: Samuel F. Lockwood, R. Preston Mason
  • Publication number: 20090118243
    Abstract: The invention relates to methods of treating ophthalmic conditions comprising administering a compound of formula A, a compound of any one of formulae 1-49, a lipoxin compound, or an oxylipin compound.
    Type: Application
    Filed: October 10, 2008
    Publication date: May 7, 2009
    Applicant: Resolvyx Pharmaceuticals, Inc.
    Inventor: Per Gjorstrup
  • Publication number: 20090062240
    Abstract: The present invention relates to a novel pharmaceutical combination, containing an inhibitor of platelet aggregation and a fÊbrate, where the inhibitor of platelet aggregation is preferably either aspirin or clopidogreL Such a pharmaceutical combination of an inhibitor of platelet aggregation and a fÊbrate is expected to be useful in the treatment and/or prevention of myocardial infarction (heart attack), cardiac arrest, peripheral vascular disease (including symptomatic carotid artery disease), congestive heart failure, ischemic heart disease, angina pectoris (including unstable angina), sudden cardiac death, unstable angina, as well as cerebrovascular events such as cerebral infarction, cerebral thrombosis, cerebral ischemia and transient ischemic attack, disorders related to bypass operations (angioplasty), fitting of endovascular prostheses and restenosis, and inflammatory disorders, including arthritic conditions such as rheumatoid arthritis and osteoarthritis, as well as asthma or related airway or resp
    Type: Application
    Filed: July 25, 2005
    Publication date: March 5, 2009
    Applicant: Fournier Laboratories Ireland Limited
    Inventors: Alan Edgar, Jean-Louis Junien, Michael Wilkins
  • Publication number: 20090053154
    Abstract: The present invention relates to a composition comprising or (preferably) consisting of 2-ethylhexyl p-methoxycinnamate and 2-ethylhexyl salicylate, the sum of the constituents (a) and (b) ranging from 50 to 100 wt. %, based on the total weight of the composition.
    Type: Application
    Filed: August 28, 2006
    Publication date: February 26, 2009
    Applicant: SYMRISE GmbH & Co. KG
    Inventor: Roland Langner
  • Publication number: 20090036413
    Abstract: Rationally designed wound care products made entirely of naturally occurring food ingredients that can be standardized and made available for the mass market using good manufacturing practice (GMP) guidelines, optionally, a safe food additive can be added. These products: are safe and effective; have an osmotic pressure compatible with optimal healing; are buffered to maintain optimal pH throughout the healing process; provide a protective barrier from further irritation and insult; control bacteria, viruses and fungi found in the skin and mucosa; nourish wounds; control excessive prolonged inflammation and thereby minimize scarring; minimize allergenic and irritation potential; are easy to use or apply; pass the preservative challenge test required for products intended for multiple use; contain fragrant essential oils to take advantage of the benefits provided by aromatherapy; can be individually optimized based on the diet of an individual or group of people.
    Type: Application
    Filed: July 29, 2008
    Publication date: February 5, 2009
    Applicant: Bill McAnalley
    Inventors: Shayne McAnalley, Bill McAnalley, Erik Aguayo